⌘K

Login Start Free

Home/Filings/4/0001062993-21-002471

4//SEC Filing

Schroder Adveq cPl Global Management III L.P. 4

Accession 0001062993-21-002471

CIK 0001656536other

View on SEC.gov Company Profile

Filed

Mar 7, 7:00 PM ET

Accepted

Mar 8, 5:35 PM ET

Size

16.7 KB

Accession

0001062993-21-002471

Insider Transaction Report

Form 4

Period: 2021-02-17

Decibel Therapeutics, Inc.DBTX

Schroder Adveq Technology IX S.C.S.

10% Owner

Transactions

Conversion
Series C Preferred Stock
2021-02-17−6,625,001→ 0 total(indirect: See footnote)
→ Common Stock (524,328 underlying)
Conversion
Series C Preferred Stock
2021-02-17−6,625,001→ 0 total(indirect: See footnote)
→ Common Stock (524,328 underlying)
Conversion
Common Stock
2021-02-17+524,328→ 524,328 total(indirect: See footnote)
Conversion
Common Stock
2021-02-17+524,328→ 524,328 total(indirect: See footnote)

Schroder Adveq Management Luxembourg Sarl

10% Owner

Transactions

Conversion
Series C Preferred Stock
2021-02-17−6,625,001→ 0 total(indirect: See footnote)
→ Common Stock (524,328 underlying)
Conversion
Common Stock
2021-02-17+524,328→ 524,328 total(indirect: See footnote)
Conversion
Common Stock
2021-02-17+524,328→ 524,328 total(indirect: See footnote)
Conversion
Series C Preferred Stock
2021-02-17−6,625,001→ 0 total(indirect: See footnote)
→ Common Stock (524,328 underlying)

Schroder Adveq cPl Global Management III L.P.

10% Owner

Transactions

Conversion
Common Stock
2021-02-17+524,328→ 524,328 total(indirect: See footnote)
Conversion
Common Stock
2021-02-17+524,328→ 524,328 total(indirect: See footnote)
Conversion
Series C Preferred Stock
2021-02-17−6,625,001→ 0 total(indirect: See footnote)
→ Common Stock (524,328 underlying)
Conversion
Series C Preferred Stock
2021-02-17−6,625,001→ 0 total(indirect: See footnote)
→ Common Stock (524,328 underlying)

Schroder Adveq cPl Global 2017 - 2019 C.V.

10% Owner

Transactions

Conversion
Series C Preferred Stock
2021-02-17−6,625,001→ 0 total(indirect: See footnote)
→ Common Stock (524,328 underlying)
Conversion
Common Stock
2021-02-17+524,328→ 524,328 total(indirect: See footnote)
Conversion
Common Stock
2021-02-17+524,328→ 524,328 total(indirect: See footnote)
Conversion
Series C Preferred Stock
2021-02-17−6,625,001→ 0 total(indirect: See footnote)
→ Common Stock (524,328 underlying)

Footnotes (3)

[F1]The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value per share, on an approximately 12.635:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date.
[F2]Held directly by Schroder Adveq Technology IX S.C.S. Schroder Adveq Management Luxembourg S.a.r.l. is the general partner of Schroder Adveq Technology IX S.C.S. Schroder Adveq Management Luxembourg S.a.r.l. disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
[F3]Held directly by Schroder Adveq cPl Global 2017 - 2019 C.V. Schroder Adveq cPl Global Management III L.P. is the general partner of Schroder Adveq cPl Global 2017 - 2019 C.V. Schroder Adveq cPl Global Management III L.P. disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.

Documents

1 file

4
form4.xmlPrimary
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Issuer

Decibel Therapeutics, Inc.

CIK 0001656536

Entity typeother

IncorporatedNetherlands Antilles

Related Parties

1

filerCIK 0001848942

Filing Metadata

Form type: 4
Filed: Mar 7, 7:00 PM ET
Accepted: Mar 8, 5:35 PM ET
Size: 16.7 KB

View on SEC.gov